VERA — Vera Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1831828 ·
Last close
$26.20
Market Cap
$1.89B
52W High
$56.05
52W Low
$25.82
ADV30
1,594,066
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 10,277,000 | 6,981,000 | -95,702,000 | -93,711,000 | 465,752,000 | 55,322,000 | 132,566,000 |
| Jun 2026 | 0 | — | -112,490,000 | -109,473,000 | 532,984,000 | 48,876,000 | 125,226,000 |
| Mar 2026 | 0 | — | -125,132,000 | -121,032,000 | 621,739,000 | 114,351,000 | 122,042,000 |
| Dec 2025 | 0 | — | -94,206,000 | -91,097,000 | 734,733,000 | 354,725,000 | 130,212,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-338,653,000
Investing CF
$45,469,000
Financing CF
$292,939,000
CapEx
$-522,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-5.67
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-991,370,000
Inventory
—
Receivables
$3,928,000
ST Investments
$450,285,000
EBIT TTM
$-394,359,000
Pretax Income TTM
$-401,894,000
Interest Exp TTM
$7,535,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,277,000
EBITDA
$-426,300,000
Free Cash Flow
$-244,618,256
Enterprise Value
$1,846,167,808
Total Cash
$384,041,984
Total Debt
$76,791,000
Shares Out
72,298,770
Trailing EPS
$-5.90
Book Value
$4.61
ROE
-113.5%
ROA
-54.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -315,473,000 | -299,615,000 | 734,733,000 | 130,212,000 | 604,521,000 | -241,104,000 |
| Dec 2024 | 0 | -167,170,000 | -152,148,000 | 655,681,000 | 78,526,000 | 577,155,000 | -134,679,000 |
| Dec 2023 | 0 | -102,012,000 | -95,990,000 | 175,546,000 | 73,861,000 | 101,685,000 | -92,181,000 |
| Dec 2022 | 0 | -90,903,000 | -89,056,000 | 131,435,000 | 54,527,000 | 76,908,000 | -67,596,000 |
TTM Snapshot
Revenues TTM
$22,956,000
NetIncome TTM
$-401,895,000
OpCashFlow TTM
—
Assets (Latest)
$532,984,000
Forward EPS
$-4.12
Max Pain — expiry 2027-01-15
max pain strike: $35.00 · spot: $25.58 · call oi: 3,496 · put oi: 15,924
Expected Move to 2027-01-15:
±$4.60
(17.98%) —
implied range
$20.98 –
$30.18
· ATM straddle on $25.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SEPN | Septerna, Inc. | $1.90B | $40.02 | — |
| ZBIO | Zenas BioPharma, Inc. | $1.88B | $27.75 | — |
| HMDCF | HUTCHMED (China) Ltd | $1.88B | $2.16 | — |
| TRVI | Trevi Therapeutics, Inc. | $1.93B | $13.51 | — |
| HRMY | Harmony Biosciences Holdings, Inc. | $1.94B | $33.01 | — |
News headlines (Yahoo Finance, 1h cache)
Vera Therapeutics Inc (VERA) (Q3 2026) Earnings Call Highlights: TRUTAKNA Launch Off to a ...
2026-11-07 08:09 · Yahoo
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 21:05 · Yahoo
Vera Therapeutics Q3 Earnings Call Highlights
2026-11-06 20:14 · Yahoo
Vera Therapeutics (VERA) Stock Looks Above Fair Value After A 148% Run
2026-11-06 14:12 · Yahoo
Vera Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
Vera Therapeutics (VERA) Q3 2026 Earnings Call Transcript
2026-11-06 07:01 · Yahoo
Vera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue Estimates
2026-11-05 21:45 · Yahoo
Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
2026-11-05 21:01 · Yahoo
Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-02 13:00 · Yahoo
Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results
2026-10-23 01:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.